Second, by targeting a convergent effector mechanism used by all IDO/TDO enzymes, indoximod may prove less sensitive to inherent or acquired resistance that may arise in patients due to IDO1 mutation, IDO1 overexpression or other target bypass mechanisms that heterogeneous cancers evolve. Here, IDO1 is linked to cancer.